01:40 PM EDT, 05/07/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target by $6 to $60, shifting to a P/E of 31x our 2026 EPS view, below its five-year historical average on near-term macroeconomic headwinds. We cut our 2025 EPS view to $1.24 from $2.00 and 2026's to $1.93 from $2.98. IPGP's Q1 results were mixed, with revenue declining 10% Y/Y to $228M, but exceeding midpoint guidance. While gross margin improved 70 bps Y/Y to 39.4%, operating margin collapsed to 0.8% from 7.6%. Book-to-bill was encouragingly above one, the highest in over two years. The company faces significant tariff headwinds, with Q2 guidance reflecting a $15M revenue delay and 150-200 bps gross margin impact as it optimizes its manufacturing footprint. We maintain our Hold rating as we see both risks and opportunities balancing: tariff uncertainty and industrial weakness offset by strong bookings momentum, promising growth in medical/advanced applications, and a robust balance sheet with $930M net cash.